SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07096999
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Castration-Resistant Prostate Carcinoma

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Key Dates

Start date
Jan 23, 2025
Status verified
Jul 2025
Primary completion
Jan 23, 2031
Completion
Jan 23, 2031

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Observational
    Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.

Primary Outcome Measure

Response and toxicity following 177Lu-RLT [ Time Frame: Up to 4 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109
James Pool
[email protected]
734-615-7391
Yuni K. Dewaraja (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Comprehensive Cancer Center· Ann Arbor, MI

Related Studies